US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Invesco Dorsey Wright Healthcare Momentum ETF

48.74

+1.803.84%

Post-market: 48.71-0.0298-0.06%17:54 EST

Volume:12.72K

Turnover:616.12K

Market Cap:122.34M

PE:15.94

High:48.84

Open:47.92

Low:47.92

Close:46.94

52wk High:54.48

52wk Low:33.56

Shares:2.51M

Float Shares:2.51M

Volume Ratio:0.70

T/O Rate:0.51%

Dividend:1.53

Dividend Rate:3.13%

EPS(TTM):3.06

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013

Ascendis Pharma announces new pooled analysis on TransCon PTH

BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1

MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PTH"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PTH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","market":"US","secType":"STK","nameCN":"Invesco Dorsey Wright Healthcare Momentum ETF","latestPrice":48.7398,"timestamp":1770411600000,"preClose":46.9395,"halted":0,"volume":12720,"hourTrading":{"tag":"盘后","latestPrice":48.71,"preClose":48.7398,"latestTime":"17:54 EST","volume":109,"amount":5305.0788,"timestamp":1770418440522,"change":-0.0298,"changeRate":-0.000611,"amplitude":0},"delay":0,"changeRate":0.03835362541143387,"floatShares":2510000,"shares":2510000,"eps":3.057033,"marketStatus":"Closed","change":1.8003,"latestTime":"02-06 16:00:00 EST","open":47.92,"high":48.84,"low":47.92,"amount":616121.20944,"amplitude":0.0196,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":3.057033,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":46.9395,"sharesOutstanding":2510000,"nav":46.97275,"aum":117901602.5,"dividendRate":0.031313,"bidAskSpread":0.003587,"postHourTrading":{"tag":"盘后","latestPrice":48.71,"preClose":48.7398,"latestTime":"17:54 EST","volume":109,"amount":5305.0788,"timestamp":1770418440522,"change":-0.0298,"changeRate":-0.000611,"amplitude":0},"volumeRatio":0.699739,"impliedVol":0.1094,"impliedVolPercentile":0.4343},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","floatShares":2510000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.699739,"shares":2510000,"dividePrice":1.5262,"high":48.84,"amplitude":0.0196,"preClose":46.9395,"low":47.92,"week52Low":33.5611,"pbRate":"--","week52High":54.475,"institutionHeld":0,"latestPrice":48.7398,"eps":3.057033,"divideRate":0.031313,"volume":12720,"delay":0,"ttmEps":3.057033,"open":47.92,"prevYearClose":49.701,"prevWeekClose":48.3136,"prevMonthClose":48.3136,"prevQuarterClose":49.701},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTH\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PTH","amount":1.52645,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2024-06-24","symbol":"PTH","amount":0.02545,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-24","defaultRemindTime":1719235800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-28","payableDate":"2024-06-24","currency":"USD","dateTimestamp":1719201600000,"payDate":"2024-06-28"},{"market":"US","date":"2023-07-17","symbol":"PTH","defaultRemindTime":1689600600000,"type":"split","dateTimestamp":1689566400000,"forFactor":1,"toFactor":3,"ratio":0.3333333333333333}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTH\",market:\"US\",,,undefined,":[{"executeDate":"2024-06-24","recordDate":"2024-06-24","paymentDate":"2024-06-28","value":0.02545,"currency":"USD"},{"executeDate":"2025-12-22","recordDate":"2025-12-22","paymentDate":"2025-12-26","value":1.52645,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PTH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PTH\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609794312","title":"Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013","url":"https://stock-news.laohu8.com/highlight/detail?id=2609794312","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609794312?lang=en_us&edition=fundamental","pubTime":"2026-02-05 08:17","pubTimestamp":1770250620,"startTime":"0","endTime":"0","summary":"According to the agreement, Everest Medicines will pay Micot an upfront payment of RMB 200 million and potential regulatory and commercial milestone payments of up to RMB 1,040 million. MT1013 has entered Phase III clinical trial in China and the relevant development expenses will be covered by Micot. The strategic collaboration is expected to complement Everest Medicines' existing renal pipeline and drive operating synergies, further strengthen the Company's commercial product portfolio, and solidify its leading position in renal and autoimmune diseases in Asia, which are key therapeutic areas of focus. The collaboration will also expand the Company's nephrology portfolio from IgA nephropathy to a broader range of chronic kidney diseases .SHPT is one of the most common and serious complications in patients with CKD. It causes di","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/everest-medicines-announces-exclusive-license-agreement-with-micot-to-commercialize-mt1013-302679600.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASN.AU","BK7095","PTH.AU","PTH","BK7504","MDCO"],"gpt_icon":0},{"id":"2581885921","title":"Ascendis Pharma announces new pooled analysis on TransCon PTH","url":"https://stock-news.laohu8.com/highlight/detail?id=2581885921","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581885921?lang=en_us&edition=fundamental","pubTime":"2025-11-07 21:35","pubTimestamp":1762522513,"startTime":"0","endTime":"0","summary":"Ascendis Pharma (ASND) announced that a new pooled analysis showed sustained and clinically meaningful improvements in renal function in adults wit...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-announces-new-pooled-analysis-on-transcon-pth-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-announces-new-pooled-analysis-on-transcon-pth-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","ASND","LU0320765992.SGD","PTH","BK4139","BK4585","LU0109394709.USD"],"gpt_icon":0},{"id":"2579297718","title":"BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2579297718","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579297718?lang=en_us&edition=fundamental","pubTime":"2025-10-29 19:00","pubTimestamp":1761735600,"startTime":"0","endTime":"0","summary":"- The CALIBRATE study of encaleret for patients with ADH1 met all pre-specified primary and key secondary efficacy endpoints - The primary endpoint was met with 76% of participants administered encale","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/29/3176268/0/en/BridgeBio-Reports-Positive-Phase-3-Topline-Results-for-Encaleret-in-Patients-with-Autosomal-Dominant-Hypocalcemia-Type-1.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH"],"gpt_icon":0},{"id":"2569867037","title":"MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension","url":"https://stock-news.laohu8.com/highlight/detail?id=2569867037","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569867037?lang=en_us&edition=fundamental","pubTime":"2025-09-22 19:00","pubTimestamp":1758538800,"startTime":"0","endTime":"0","summary":"Statistically significant responder rate achieved at 12 weeks with zero contribution from rescue therapy (PRN) and further improvement sustained in open-label extension (OLE) Positive findings in bone","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/22/3153770/0/en/MBX-Biosciences-Announces-Once-Weekly-Canvuparatide-Achieved-Primary-Endpoint-in-Phase-2-Trial-with-63-Responder-Rate-at-12-Weeks-79-Responder-Rate-at-6-Months-in-Open-Label-Extens.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4092","BK4218","BK4181","PK","PRN","HP","MBX","PTH","PBH","BK4007"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/PTH\",params:#limit:6,delay:false,,,undefined,":[]}}